170 related articles for article (PubMed ID: 1922797)
1. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Cedarbaum JM; Olanow CW
Neurology; 1991 Oct; 41(10):1567-70. PubMed ID: 1922797
[TBL] [Abstract][Full Text] [Related]
2. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Olanow CW; Gauger LL; Cedarbaum JM
Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
[TBL] [Abstract][Full Text] [Related]
3. Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa.
Manyam BV
Arch Neurol; 1982 Jul; 39(7):391-2. PubMed ID: 7103767
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid indices of blood-brain barrier permeability following adrenal-brain transplantation in patients with Parkinson's disease.
Ahlskog JE; Tyce GM; Kelly PJ; van Heerden JA; Stoddard SL; Carmichael SW
Exp Neurol; 1989 Aug; 105(2):152-61. PubMed ID: 2753115
[TBL] [Abstract][Full Text] [Related]
5. Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: clinical outcome and neurochemical studies.
Ahlskog JE; Kelly PJ; van Heerden JA; Stoddard SL; Tyce GM; Windebank AJ; Bailey PA; Bell GN; Blexrud MD; Carmichael SW
Mayo Clin Proc; 1990 Mar; 65(3):305-28. PubMed ID: 2314121
[TBL] [Abstract][Full Text] [Related]
6. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.
Hauser RA; Ellenbogen AL; Metman LV; Hsu A; O'Connell MJ; Modi NB; Yao HM; Kell SH; Gupta SK
Mov Disord; 2011 Oct; 26(12):2246-52. PubMed ID: 21755537
[TBL] [Abstract][Full Text] [Related]
7. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.
Goetz CG; Tanner CM; Shannon KM; Carroll VS; Klawans HL; Carvey PM; Gilley D
Neurology; 1988 Jul; 38(7):1143-6. PubMed ID: 3290706
[TBL] [Abstract][Full Text] [Related]
8. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
[TBL] [Abstract][Full Text] [Related]
9. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
10. Study on the striatal dopamine availability in Parkinson's disease.
Indo T
Jpn J Med; 1984 Aug; 23(3):228-36. PubMed ID: 6492486
[TBL] [Abstract][Full Text] [Related]
11. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
12. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
[TBL] [Abstract][Full Text] [Related]
13. Motor function in the normal aging population: treatment with levodopa.
Newman RP; LeWitt PA; Jaffe M; Calne DB; Larsen TA
Neurology; 1985 Apr; 35(4):571-3. PubMed ID: 3982646
[TBL] [Abstract][Full Text] [Related]
14. CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
Eldrup E; Mogensen P; Jacobsen J; Pakkenberg H; Christensen NJ
Acta Neurol Scand; 1995 Aug; 92(2):116-21. PubMed ID: 7484057
[TBL] [Abstract][Full Text] [Related]
15. Controlled release levodopa treatment of motor fluctuations in Parkinson's disease.
Juncos JL; Fabbrini G; Mouradian MM; Serrati C; Kask AM; Chase TN
J Neurol Neurosurg Psychiatry; 1987 Feb; 50(2):194-8. PubMed ID: 3572434
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics.
Davis TL; Brughitta G; Baronti F; Mouradian MM
Neurology; 1991 May; 41(5):630-3. PubMed ID: 2027476
[TBL] [Abstract][Full Text] [Related]
17. Dopamine/L-dopa ratio in cerebrospinal fluid of parkinsonian patients treated with L-dopa + benserazide.
Fekete M; Tárczy M; Bihari K; Katona G
Psychopharmacology (Berl); 1984; 82(1-2):93-4. PubMed ID: 6420835
[TBL] [Abstract][Full Text] [Related]
18. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
[TBL] [Abstract][Full Text] [Related]
19. Fluctuations in plasma dopamine level impair memory in Parkinson's disease.
Huber SJ; Shulman HG; Paulson GW; Shuttleworth EC
Neurology; 1987 Aug; 37(8):1371-5. PubMed ID: 3614661
[TBL] [Abstract][Full Text] [Related]
20. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Fernandez HH; Odin P
Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
